New ‘Ozempic pill' is better than ‘skinny jabs' and helps you lose weight even faster, study suggests
A NEW 'Ozempic pill' leads to faster weight loss than the popular 'skinny jabs', studies have suggested.
The new weight loss medication, which can also be offered by injection, can help patients lose a significant amount of weight.
Advertisement
1
The new weight loss pill has seen promising results in early trials
Credit: Getty
An early study found that patients who received amycretin as a weekly jab lost 24% of their body weight after 36 weeks of treatment.
But initial trials assessing a tablet form of the jab saw promising results with patients losing an average 13% of bodyweight in just three months.
This suggests the drug leads to greater weight loss than Wegovy, the 'sister jab' of Ozempic.
Such treatments have been called transformative by NHS leaders.
Advertisement
Read more Health news
It's estimated that around 1.5 million Brits currently receive weight loss jabs through specialist weight loss services or private prescriptions.
But weight pills offer a new hope to millions looking to lose weight as the injections put additional pressure on an overstretched NHS.
However, further clinical trials are needed before the treatment can be made available in the UK.
This could take several years and there's no guarantee that regulators will approve the use of the drug.
Advertisement
Most read in Health
Amycretin, made by Novo Nordisk, contains semaglutide, the same active ingredient as Ozempic and Wegovy and helps control blood sugar and appetite.
It targets specific receptors in the body - the GLP-1 and amylin receptors - helping you feel full and stops overeating.
An early trial published in The Lancet found that 125 adults taking weekly injections containing higher doses of the drug lost nearly a quarter of their body weight after 36 weeks.
It also showed signs of improving blood sugar levels.
Advertisement
However, there were some mild to moderate side effects including nausea and vomiting but these were resolved by the end of the treatment.
Experts said that the medicine appeared "safe and tolerable" but further studies were needed to fully assess the drug.
But a second trial, also published in The Lancet, assessed the drug in tablet form in 144 people.
Those taking the highest dose of 100mg lost 13% of their body weight over four months.
Advertisement
Weight Loss Jabs - Pros vs Cons
The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people who were overweight or obese.
"Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen."
As with the first trial, there were also some mild to moderate side effects including loss of appetite and similar gastrointestinal issues.
It comes as a separate study examined the effects of the weight-loss jab, Wegovy, at higher doses.
Advertisement
The researchers found that giving patients 7.2mg of Wegovy once a week led to an average weight loss of 21%, with a third of participants losing 25% of their body weight over 72 weeks.
The studies were also presented to the American Diabetes Association's Scientific Sessions in
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Extra.ie
an hour ago
- Extra.ie
New weight loss pill set to rival 'fat jab' shows promising results in early trials
A new weight loss treatment that can be taken as either a daily pill or a weekly injection has shown very promising results in initial trials, according to a new study. In one of the tests, 125 adults were assigned weekly injections of a drug called 'AMYCRETIN', and early results showed that those receiving the 60 milligram dose lost nearly a quarter of their body weight over 36 weeks. 'Amycretin' is a 'unimolecular long-acting GLP-1 and amylin receptor agonist' under development by Novo Nordisk, to provide a treatment for adults with obesity and as a treatment for adults with type 2 diabetes. Pic: Shutterstock If the initial results turn out to be effective in the long run, this may make 'Amycretin' a more effective treatment for obesity than other weight loss drugs like Weygovy and Ozempic. Another trial enrolled 144 adults to test the 'pill version' of 'Amycretin'. Those who took the 100 milligram daily tablet lost an average of 13.1 percent of their weight over 12 weeks. Novo-Nordisk, who are heading up the research into this new medication says initial trials suggest Amycretin could be on the market by next year. Pic: Getty Images The strongest prescription weight loss medication currently approved by the FDA is Semaglutide, marketed under brand names like Wegovy and Ozempic (for diabetes, also used off-label for weight loss).
The Irish Sun
5 hours ago
- The Irish Sun
New ‘Ozempic pill' is better than ‘skinny jabs' and helps you lose weight even faster, study suggests
A NEW 'Ozempic pill' leads to faster weight loss than the popular 'skinny jabs', studies have suggested. The new weight loss medication, which can also be offered by injection, can help patients lose a significant amount of weight. Advertisement 1 The new weight loss pill has seen promising results in early trials Credit: Getty An early study found that patients who received amycretin as a weekly jab lost 24% of their body weight after 36 weeks of treatment. But initial trials assessing a tablet form of the jab saw promising results with patients losing an average 13% of bodyweight in just three months. This suggests the drug leads to greater weight loss than Wegovy, the 'sister jab' of Ozempic. Such treatments have been called transformative by NHS leaders. Advertisement Read more Health news It's estimated that around 1.5 million Brits currently receive weight loss jabs through specialist weight loss services or private prescriptions. But weight pills offer a new hope to millions looking to lose weight as the injections put additional pressure on an overstretched NHS. However, further clinical trials are needed before the treatment can be made available in the UK. This could take several years and there's no guarantee that regulators will approve the use of the drug. Advertisement Most read in Health Amycretin, made by Novo Nordisk, contains semaglutide, the same active ingredient as Ozempic and Wegovy and helps control blood sugar and appetite. It targets specific receptors in the body - the GLP-1 and amylin receptors - helping you feel full and stops overeating. An early trial published in The Lancet found that 125 adults taking weekly injections containing higher doses of the drug lost nearly a quarter of their body weight after 36 weeks. It also showed signs of improving blood sugar levels. Advertisement However, there were some mild to moderate side effects including nausea and vomiting but these were resolved by the end of the treatment. Experts said that the medicine appeared "safe and tolerable" but further studies were needed to fully assess the drug. But a second trial, also published in The Lancet, assessed the drug in tablet form in 144 people. Those taking the highest dose of 100mg lost 13% of their body weight over four months. Advertisement Weight Loss Jabs - Pros vs Cons The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people who were overweight or obese. "Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen." As with the first trial, there were also some mild to moderate side effects including loss of appetite and similar gastrointestinal issues. It comes as a separate study examined the effects of the weight-loss jab, Wegovy, at higher doses. Advertisement The researchers found that giving patients 7.2mg of Wegovy once a week led to an average weight loss of 21%, with a third of participants losing 25% of their body weight over 72 weeks. The studies were also presented to the American Diabetes Association's Scientific Sessions in
The Irish Sun
6 hours ago
- The Irish Sun
Brit fighting for life after catching deadly disease on all-inclusive at hols hotspot
A BRITISH tourist is fighting for her life after catching a deadly disease while on her all-inclusive holiday in Greece. Donna Jobling, 57, from west Hull, came down with Legionnaires' disease on the island of Crete, and is in intensive care. 2 Donna Jobling, 57, of west Hull, is fighting for her life in hospital Credit: MEN Media 2 Donna was on holiday in Crete with her husband and two friends Credit: Getty She is receiving urgent treatment at Venizeleio Hospital in Heraklion after falling ill just days into the trip. Donna was holidaying with her husband Sidney and friends Paula and Nicolas Mason, also of Hull. The group had been enjoying a £1,500-per-couple all-inclusive trip when Donna fell ill. She developed a chest infection and needed lots of rest, and then became seriously ill two days later. Donna, who suffers from "complex" medical conditions including epilepsy, was taken to hospital on June 11 and doctors put her in an induced coma. Tests confirmed she had contracted Legionnaires' disease, which triggered acute respiratory failure and Her "devastated" family has flown out to be by her side. Neice Claire, 42, has been back-and-forth between Crete and Hull. Most read in The Sun She is currently in East Yorkshire to obtain Donna's insurance documents before flying back out. The couple was travelling with Easyjet. A spokesperson for the company said: "We're so sorry to hear that Ms Jobling is unwell, and we're continuing to support her and her family in every way we can. "As soon as we were made aware of reports of illness, we immediately took action and contacted customers who were already staying in the hotel, or due to travel in the next four weeks, to provide alternative hotel options." More to follow... For the latest news on this story keep checking back at The Sun Online is your go-to destination for the best celebrity news, real-life stories, jaw-dropping pictures and must-see video. Like us on Facebook at
